

IN THE CLAIMS:

Please amend claims 1 and 9-11 as indicated below.


Please cancel claim 2.

Please add claims 31 and 32.

This listing of claims below will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A prodrug of the general formula I



Formula I

or a pharmaceutically acceptable salt thereof, wherein:

R₁ is a saturated or unsaturated, straight-chain or branched, substituted or unsubstituted hydrocarbon chain having from 2 to 30 carbon atoms;

R₂ is H or a phospholipid head group;

Z is saturated or unsaturated, straight-chain or branched, substituted or unsubstituted hydrocarbon chain having from 2 to 15 carbon atoms, which may include cyclic elements and is optionally interrupted by one or more atoms selected from oxygen and sulfur atoms;

X is a direct covalent bond or selected from the group consisting of O, S, NH and C(O) groups; and

D is the residue of an anti-proliferative drug, and wherein the anti-proliferative drug is methotrexate or pharmaceutically acceptable derivatives thereof,

wherein the bound anti-proliferative drug residue is an inactive form of the drug which is selectively activated in cells and tissues with elevated phospholipase activity.

2. (Canceled)
3. (Withdrawn) The prodrug according to claim 1, wherein the anti-proliferative drug is 2'-deoxy-5-fluorouridine and pharmaceutically acceptable derivatives thereof.
4. (Original) The prodrug according to claim 1, wherein an ester bond at position sn-2 of the phospholipid of the general formula I is cleaveable by a lipase.
5. (Original) The prodrug according to claim 4, wherein said phospholipase is phospholipase A₂ (PLA₂).
6. (Original) The prodrug according to claim 1, wherein R1 is an hydrocarbon chain having from 5 to 20 carbon atoms.
7. (Original) The prodrug according to claim 1, wherein R1 is an hydrocarbon chain having 15 or 17 carbon atoms.
8. (Original) The prodrug according to claim 1, wherein R2 is selected from the group consisting of choline, ethanolamine, inositol and serine.
9. (Currently Amended) The compound according to claim 1 selected from the

group consisting of:

1-Stearoyl-2-[3-[α -MTX amido)-Propanoyl]-sn-Glycero-3-~~Phosphatidyletholine~~
phosphocholine,

1- Stearoyl-2-[3-[γ -dodecylate- α -MTX amido)-Propanoyl]-snGlycero-3-
~~Phosphatidyletholine~~ phosphocholine,

1-Stearoyl-2-[4-(α -MTX amido)-Butanoyl]-sn-Glycero-3-~~Phosphatidyletholine~~
phosphocholine,

1- Stearoyl-2-[6-(α -MTX-amido)-Hexanoyl]-sn-Glycero-3-~~Phosphatidyletholine~~
phosphocholine,

1- Stearoyl-2-[8-(α -MTX-amido)-Octanoyl]-sn-Glycero-3-~~Phosphatidyletholine~~
phosphocholine, and

1- Stearoyl-2-[3-(α -dodecylate- γ -MTX-amido)-Propanoyl]-sn-Glycero-3-
~~Phosphatidyletholine~~ phosphocholine, and

~~1-Stearoyl-2-[5''-(2'' deoxy-5' fluorouridine-5'')-3''',3''' dimethyl] glutaroyl 1''' sn-~~
~~glycero-3-phosphatidyletholine.~~

10. (Currently Amended) The prodrug according to claim 1, which is 1-Stearoyl-2-
[3-[α -MTX amido)-Propanoyl]-sn-Glycero-3-~~Phosphatidyletholine~~ phosphocholine.

11. (Currently Amended) The prodrug according to claim 1, which is 1- Stearoyl-2-
[3-(α -dodecylate- γ -MTX-amido)-Propanoyl]-sn-Glycero-3-~~Phosphatidyletholine~~ phosphocholine.

12. (Previously Amended) A pharmaceutical composition comprising, as an
active ingredient, a prodrug of the general formula I according to claim 1 and a pharmaceutically
acceptable carrier.

13. (Original) The pharmaceutical composition according to claim 12, further
comprising an additional neoplastic agent.

14. (Previously Amended) The pharmaceutical composition according to claim
12, which is suitable for oral, ocular, nasal, parenteral, topical or rectal administration.

15. (Previously Amended) The pharmaceutical composition according to claim 12, which is suitable for oral administration, intravenous administration or topical administration.

16. (Previously Amended) The pharmaceutical composition according to claim 12, in the form of solutions, suspensions, capsules, tablets, aerosols, gels, ointments or suppositories.

17. (Canceled)

18. (Original) A method for treatment of a disease or disorder related to an inflammatory condition comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 12.

19. (Original) The method according to claim 18, wherein said disease or disorder related to an inflammatory condition is selected from the group consisting of granulomatous diseases, arthritis, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic sclerosis, asthma, psoriasis, systemic lupus erythematosus, inflammatory bowel syndromes and migraines.

20. (Original) A method for treatment of a disease or disorder according related to a degenerative or atrophic condition comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 12.

21. (Original) The method according to claim 20, wherein said disease or disorder related to a degenerative or atrophic condition is a central or peripheral neurological disease or disorder.

22. (Original) The method according to claim 20, wherein said disease or disorder related to a degenerative or atrophic condition is selected from the group consisting of autoimmune, cerebrovascular and neurodegenerative diseases and disorders such as idiopathic

dementia, vascular dementia, multi-infarct dementia, traumatic dementia, Alzheimer's disease, Pick's disease, Huntington's disease, dementia paralytica, Parkinson's disease, diabetic neuropathy, amyotrophic lateral sclerosis, ischemia of the optic nerve, age-related macular degeneration, stroke and ischemia.

23. (Original) A method for treatment of a disease or disorder related to uncontrolled cell growth comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 12.

24. (Original) The method according to claim 23, wherein said disease or disorder related to uncontrolled cell growth is a neoplastic growth.

25. (Original) The method according to claim 24 wherein said neoplastic growth is a primary or a secondary tumor.

26. (Original) The method according to claim 24 wherein said neoplastic growth is a drug-resistant tumor.

27. (Original) The method according to claim 24 wherein said neoplastic growth is a methotrexate-resistant tumor.

28. (Original) The method according to claim 24 wherein said neoplastic growth is a multidrug-resistant tumor.

29. (Original) The method according to claim 23, wherein said disease or disorder related to uncontrolled cell growth is selected from the group consisting of psoriasis, lymphocytic leukemia, myelogenous leukemia, Burkitt's lymphoma, non-Hodgkin's lymphomas, mycosis fungoides, osteosarcoma, hydatidiform mole, trophoblastic diseases such as chorioadenoma destruens and choriocarcinoma, and carcinomas of the head and neck, breast, liver, lung, colon, ovary, cervix, urinary, bladder, prostate, pancreas, skin, the gastrointestinal tract and the oropharyngeal areas.

30. (Previously Presented) A method of manufacturing a medicament which comprises combining a prodrug of the general formula I according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
31. (New) The prodrug according to claim 1, wherein the methotrexate is bound into Formula I at the α -carboxyl group of methotrexate.
32. (New) The prodrug according to claim 1, wherein the methotrexate is bound into Formula I at the γ -carboxyl group of methotrexate.